Analyzing Mangoceuticals (MGRX) & The Competition

Mangoceuticals (NASDAQ:MGRX) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its peers? We will compare Mangoceuticals to similar businesses based on the strength of its risk, analyst recommendations, valuation, dividends, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Mangoceuticals and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1	0	0	0	1.00
Mangoceuticals Competitors	1836	7670	13196	813	2.55

As a group, “Healthcare Providers & Services” companies have a potential upside of 12.65%. Given Mangoceuticals’ peers stronger consensus rating and higher probable upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Mangoceuticals and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$460,000.00	-$20.64 million	-0.24
Mangoceuticals Competitors	$21.29 billion	$288.48 million	7.04

Mangoceuticals’ peers have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Mangoceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Mangoceuticals Competitors	-7.83%	-141.62%	-1.53%

Volatility & Risk

Mangoceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Mangoceuticals’ peers have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Summary

Mangoceuticals peers beat Mangoceuticals on 10 of the 13 factors compared.

Mangoceuticals Company Profile

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.